Evidence map›Paper›PMID 35478326›Full record

ArticleMicrobial biotechnology2022

Standardization of regulatory nodes for engineering heterologous gene expression: a feasibility study.

Pablo I Nikel, Ilaria Benedetti, Nicolas T Wirth, Víctor de Lorenzo, Belén Calles

Open access · goldAbstract read
In one paragraph

Article in Microbial biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Going beyond size: exploring the metabolic burden inSynthetic biology (Oxford, England) · 2026
    Article
  8. Article
  9. Leveraging EngineeredACS synthetic biology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Pablo I NikelThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs Lyngby, 2800, Denmark.ORCID 0000-0002-9313-7481
Ilaria BenedettiSystems and Synthetic Biology Program, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, 28049, Spain.
Nicolas T WirthThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs Lyngby, 2800, Denmark.ORCID 0000-0003-0799-1321
Víctor de LorenzoSystems and Synthetic Biology Program, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, 28049, Spain.ORCID 0000-0002-6041-2731
Belén CallesSystems and Synthetic Biology Program, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, 28049, Spain.ORCID 0000-0003-0603-0115
Centro Nacional de Biotecnología · ESNovo Nordisk Foundation · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential of LacI/P

Indexed as

Escherichia coliGenetic VectorsFeasibility StudiesGene ExpressionPlasmidsPromoter Regions, GeneticReference Standards

Identifiers

PMID35478326
PMCPMC9328736
OpenAlexW4225001186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.